[go: up one dir, main page]

Service et al., 1980 - Google Patents

Characteristics of glycemic stability

Service et al., 1980

Document ID
3328815799983178803
Author
Service F
Nelson R
Publication year
Publication venue
Diabetes Care

External Links

Snippet

Glucose homeostasis in healthy subjects is characterized by postmeal glucose increases of about 40 mg/dl, peaks at about 45 min, decreases close to antecibal levels 1 h after the peak, and no spontaneous oscillations until the next meal. Diabetes is characterized by …
Continue reading at diabetesjournals.org (other versions)

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
    • A61M5/14—Infusion devices, e.g. infusing by gravity; Blood infusion; Accessories therefor
    • A61M5/168—Means for controlling media flow to the body or for metering media to the body, e.g. drip meters, counters; Monitoring media flow to the body
    • A61M5/172—Means for controlling media flow to the body or for metering media to the body, e.g. drip meters, counters; Monitoring media flow to the body electrical or electronic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
    • A61M5/14—Infusion devices, e.g. infusing by gravity; Blood infusion; Accessories therefor
    • A61M5/142—Pressure infusion, e.g. using pumps
    • A61M5/14244—Pressure infusion, e.g. using pumps adapted to be carried by the patient, e.g. portable on the body
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2230/00—Measuring parameters of the user
    • A61M2230/20—Blood composition characteristics
    • A61M2230/201—Glucose concentration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Detecting, measuring or recording for diagnostic purposes; Identification of persons
    • A61B5/145—Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue
    • A61B5/14532—Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue for measuring glucose, e.g. by tissue impedance measurement

Similar Documents

Publication Publication Date Title
Service et al. Characteristics of glycemic stability
Graf et al. Glycosylated hemoglobin in normal subjects and subjects with maturity-onset diabetes evidence for a saturable system in man
Service et al. Mean amplitude of glycemic excursions, a measure of diabetic instability
US8114023B2 (en) Analyte sensing and response system
Greenfield et al. Assessment of insulin resistance with the insulin suppression test and the euglycemic clamp
Clarke et al. Closed-loop artificial pancreas using subcutaneous glucose sensing and insulin delivery and a model predictive control algorithm: the Virginia experience
Amiel et al. Rate of glucose fall does not affect counterregulatory hormone responses to hypoglycemia in normal and diabetic humans
US20110054391A1 (en) Analyte sensing and response system
Genuth Plasma insulin and glucose profiles in normal, obese, and diabetic persons
Raskin et al. Changes in glucagon levels after four to five weeks of glucoregulation by portable insulin infusion pumps
Hanna et al. Insulin, glucagon, and amino acids during glycemic control by the artificial pancreas in diabetic man
Amiel et al. Exaggerated epinephrine responses to hypoglycemia in normal and insulin-dependent diabetic children
Bolli et al. Mechanisms of glucagon secretion during insulin-induced hypoglycemia in man. Role of the beta cell and arterial hyperinsulinemia.
Binder et al. Residual beta-cell function and its metabolic consequences
Schiffrin et al. Improved control in diabetes with continuous subcutaneous insulin infusion
Jenkins et al. Regulation of hepatic glucose output during moderate exercise in non-insulin-dependent diabetes
Geffner et al. Early-morning hyperglycemia in diabetic individuals treated with continuous subcutaneous insulin infusion
Youssef et al. A controlled study of the effectiveness of an adaptive closed-loop algorithm to minimize corticosteroid-induced stress hyperglycemia in type 1 diabetes
Lardinois et al. Glyburide in non-insulin-dependent diabetes: its therapeutic effect in patients with disease poorly controlled by insulin alone
Jacobs et al. Development of a fully automated closed loop artificial pancreas control system with dual pump delivery of insulin and glucagon
Schiffrin et al. Combined continuous subcutaneous insulin infusion and multiple subcutaneous injections in type I diabetic patients
King Mean basal insulin dose is 0.2 U/kg/d at near normal glycaemia for type 1 or 2 diabetes on continuous subcutaneous insulin infusion or once‐nightly basal insulin.
Schiffrin et al. Predicting nocturnal hypoglycemia in patients with type I diabetes treated with continuous subcutaneous insulin infusion
van Bon et al. Postprandial glycemic excursions with the use of a closed-loop platform in subjects with type 1 diabetes: a pilot study
Schiffrin Treatment of insulin-dependent diabetes with multiple subcutaneous insulin injections